723 related articles for article (PubMed ID: 33142413)
21. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
22. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
23. Induction of apoptosis, cytotoxicity and radiosensitization by novel 3,4-dihydroquinazolinone derivatives.
Soliman AM; Khalil A; Ramadan E; Ghorab MM
Bioorg Med Chem Lett; 2021 Oct; 49():128308. PubMed ID: 34363937
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
25. Quinazolin-4(3
Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and molecular modeling studies of 2-styrylquinazoline derivatives as EGFR inhibitors and apoptosis inducers.
Amin NH; Elsaadi MT; Zaki SS; Abdel-Rahman HM
Bioorg Chem; 2020 Dec; 105():104358. PubMed ID: 33074119
[TBL] [Abstract][Full Text] [Related]
27. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
28. Quinazoline-sulfonamides as potential antitumor agents: synthesis and biological testing.
Alafeefy AM; Alqasoumi SI; Ashour AE; Alshebly MM
J Enzyme Inhib Med Chem; 2013 Apr; 28(2):375-83. PubMed ID: 22468752
[TBL] [Abstract][Full Text] [Related]
29. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Evaluation of Some Dibromoquinazoline-sulphonamide Hybrids and some Schiff´s Base Analogs for their Cytotoxic Activity.
Ahmed MF; El-Haggar R
Anticancer Agents Med Chem; 2017 Nov; 17(11):1563-1569. PubMed ID: 28356022
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W
Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040
[TBL] [Abstract][Full Text] [Related]
32. 4t-CHQ a Spiro-Quinazolinone Benzenesulfonamide Derivative Induces G
Rahimian A; Mahdavi M; Rahbarghazi R; Charoudeh HN
Anticancer Agents Med Chem; 2019; 19(11):1340-1349. PubMed ID: 30868965
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
[No Abstract] [Full Text] [Related]
34. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
35. From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity.
El-Shershaby MH; Ghiaty A; Bayoumi AH; Al-Karmalawy AA; Husseiny EM; El-Zoghbi MS; Abulkhair HS
Bioorg Med Chem; 2021 Jul; 42():116266. PubMed ID: 34126285
[TBL] [Abstract][Full Text] [Related]
36. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
37. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
38. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
Yassen AS; Elshihawy HE; Said MM; Abouzid KA
Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
[TBL] [Abstract][Full Text] [Related]
39. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
Ahmed MF; Magdy N
Anticancer Agents Med Chem; 2017; 17(6):832-838. PubMed ID: 27671305
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]